Vilazodone
Clinical data | |
---|---|
Pronunciation | /vɪˈlæzədoʊn/ vi-LAZ-ə-dohn |
Trade names | Viibryd |
Other names | EMD-68843; SB-659746A |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611020 |
License data |
|
Serotonin modulator[1] | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 72% (oral, with food)[5] |
Metabolism | Liver via CYP3A4[5] |
Elimination half-life | 25 hours[5] |
Excretion | Faecal and renal[5] |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Vilazodone, sold under the brand name Viibryd among others, is a
Common side effects include nausea, diarrhea, and trouble sleeping.
Vilazodone was approved for medical use in the United States in 2011[1] and in Canada in 2018.[8] In 2019, it was the 334th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions.[9] The drug lost patent protection in June 2022 for adults and in July 2023 for pediatrics.[10] Generic versions have been approved by the U.S. Food and Drug Administration (FDA).[11][12]
Medical uses
Seven controlled efficacy trials were conducted of vilazodone for treatment of major depressive disorder (MDD).[13] Five of these trials showed no significant influence of vilazodone over placebo on depressive symptoms.[13] In the remaining two trials, small but significant advantages of vilazodone over placebo were found.[13] According to these two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment.[14] After eight weeks it resulted in a 13% greater response than placebo.[14] Remission rates, however, were not significantly different versus placebo.[14]
According to the US Food and Drug Administration (FDA) staff in 2011, "it is unknown whether vilazodone has any advantages compared to other drugs in the antidepressant class."[15] A 2019 review stated that "present studies do not suggest the superiority of vilazodone compared with other antidepressants."[16]
Development of vilazodone for generalized anxiety disorder (GAD) has been stopped as of 2017.[17] While there is tentative evidence of a small benefit in GAD, there is a high rate of side effects.[18]
Adverse effects
In September 2016, the FDA wrote a letter to Forest Labs requiring a new warning to be added to the label related to a link between the drug and acute pancreatitis and sleep paralysis.[19]
After a one-year,
- Very common adverse effects (incidence >10%)
- Nausea
- Diarrhea
- Headache
- Common adverse effects (1–10% incidence)
- Vomiting
- Dry mouth
- Dizziness
- Insomnia
- Uncommon adverse effects (0.1–1% incidence)
- Somnolence
- Paraesthesia
- Tremor
- Abnormal dreams
- Libido decreased
- Restlessness
- Akathisia
- Restless legs syndrome
- Abnormal orgasms (men only)
- Delayed ejaculations (men only)
- Erectile dysfunction (men only)
- Fatigue
- Feeling jittery
- Palpitations
- Ventricular premature contractions
- Arthralgia
- Increased appetite
- Rare adverse effects (<0.1% incidence)
- Serotonin syndrome—a serious adverse effect characterised by:
- Nausea
- Vomiting
- Mental status change (e.g. confusion, hallucinations, agitation, coma, stupor)
- Muscle rigidity
- Tremor
- Myoclonus
- Hyperreflexia—overresponsive/overactive reflexes
- Hyperthermia—elevated body temperature
- Autonomic instability (e.g. tachycardia, dizziness, abnormally excessive sweating, etc.)
- Mania/hypomania—a potentially dangerously elated/agitated mood. Every antidepressant has the potential to induce these psychiatric reactions. They are particularly problematic in those with a history of hypomania/mania such as those with bipolar disorder.[21]
- Unknown-incidence adverse effects
- Suicidal ideation—all antidepressants can cause suicidal ideation especially in young adults and adolescents under the age of 25.
- Abnormal bleeding—the SSRIs are known for their ability to increase the incidence of gastrointestinal bleeds and other bleeding abnormalities.[21][22][23]
- Seizures
- antidiuretic hormonecausing potentially-fatal electrolyte abnormalities (such as hyponatraemia).
- Hyponatraemia(a complication of the former)—low blood sodium.
Pregnancy
Antidepressant exposure (including vilazodone) is associated with shorter average duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g), and lower Apgar scores (by <0.4 points).[24][25] It is uncertain whether there is an increased rate of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy.[26][27]
Pharmacology
Pharmacodynamics
Vilazodone acts as a
Pharmacokinetics
Vilazodone is best absorbed with food and has a bioavailability of 72% under fed conditions. The Cmax increased between 147 and 160% and the AUC increased between 64 and 85% of vilazodone when it was administered with either a fatty or light meal.[33]
History
It was developed by
References
- ^ a b c d e f g h i "Vilazodone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved March 3, 2019.
- ^ Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.
- ^ "Viibryd Product information". Health Canada. April 25, 2012. Retrieved June 10, 2022.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. May 4, 2016. Retrieved April 7, 2024.
- ^ a b c d e f g "Viibryd (vilazodone hydrochloride) tablet Viibryd (vilazodone hydrochloride) kit [Forest Laboratories, Inc.]". DailyMed. Forest Laboratories, Inc. December 2012. Archived from the original on October 29, 2013. Retrieved October 28, 2013.
- ^ S2CID 4572360.
- ^ "Vilazodone (Viibryd) Use During Pregnancy". Drugs.com. Retrieved March 21, 2019.
- ^ "Drug Product Database Online Query". Health Canada. Government of Canada. April 25, 2012. Retrieved May 18, 2020.
- ^ "Vilazodone - Drug Usage Statistics". ClinCalc. Archived from the original on July 8, 2020. Retrieved October 16, 2021.
- ^ "Generic Viibryd Availability".
- ^ "Vilazodone: FDA-Approved Drugs".
- ^ "2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). January 21, 2021. Retrieved June 10, 2022.
- ^ PMID 25279271.
- ^ S2CID 10702028.
- PMID 21951984.
- S2CID 53773793.
- ^ "New Medicines Newsletter" (PDF). NHS. Archived from the original (PDF) on March 21, 2019. Retrieved March 21, 2019.
- PMID 28483071.
- ^ "SUPPLEMENT APPROVAL" (PDF). U.S. Food and Drug Administration (FDA).
- ^ "FDA approves Clinical Data Inc's antidepressant". Reuters. January 22, 2011. Archived from the original on January 27, 2011.
- ^ a b Australian Medicines Handbook 2013. The Australian Medicines Handbook Unit Trust; 2013.
- ^ Taylor D, Paton C, Kapur S, Taylor D. The Maudsley prescribing guidelines in psychiatry. 11th ed. Chichester, West Sussex: John Wiley & Sons; 2012.
- ^ Wang Y-P, Chen Y-T, Tsai C-F, Li S-Y, Luo J-C, Wang S-J, et al. Short-Term Use of Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Bleeding. Am J Psychiatry [Internet]. 2013 Sep 13 [cited 2013 Oct 6]; Available from: http://ajp.psychiatryonline.org/article.aspx?articleid=1738031
- PMID 23446732.
- PMID 16015372.
- PMID 19776103.
- PMID 24941178.
- ^ PMID 15740724.
- S2CID 12020750.
- S2CID 19662281.
- PMID 19499624.
- PMID 22935937.
- PMID 22346333.
- ^ "Xconomy: Blend Therapeutics Taps Former Clinical Data Chief Fromkin As New CEO". xconomy.com. April 13, 2015. Archived from the original on September 9, 2017. Retrieved May 6, 2018.